Adiponectin -11377C/G and +276G/T Polymorphisms affect Adiponectin Levels but do not Modify Responsiveness to Therapy in Resistant Hypertension

Basic and Clinical Pharmacology and Toxicology

Volumn 117, Issue 1, 2015, Pages 65-72

  de Faria, Ana Paula C ^a   Modolo, Rodrigo ^a   Sabbatini, Andréa R ^a   Barbaro, Natália R ^a   Corrêa, Nathália B ^a   Brunelli, Veridiana ^a   Tanus Santos, José E ^b   Fontana, Vanessa ^c   Moreno, Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIHYPERTENSIVE AGENT; ADIPOQ PROTEIN, HUMAN; BIOLOGICAL MARKER;

ADULT; ALLELE; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART LEFT VENTRICLE MASS; HUMAN; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE PRESSURE; PULSE WAVE; RESISTANT HYPERTENSION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; DRUG RESISTANCE; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HOMOZYGOTE; HYPERTENSION; MIDDLE AGED; PHENOTYPE; RISK FACTOR;

ADIPONECTIN; AGED; ANTIHYPERTENSIVE AGENTS; BIOMARKERS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84930762926     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12368     Document Type: Article

References (43)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19.
2. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension 2008;51:8-14.
3. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009;150:776-83.
4. Sutton-Tyrrell K, Newman A, Simonsick EM, Havlik R, Pahor M, Lakatta E et al. Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. Hypertension 2001;38:429-33.
5. Salles GF, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension 2007;50:723-8.
6. Salles GF, Cardoso CR, Pereira VS, Fiszman R, Muxfeldt ES. Prognostic significance of a reduced glomerular filtration rate and interaction with microalbuminuria in resistant hypertension: a cohort study. J Hypertens 2011;29:2014-23.
7. Kurukulasuriya LR, Stas S, Lastra G, Manrique C, Sowers JR. Hypertension in obesity. Med Clin North Am 2011;95:903-17.
8. Sabbatini AR, Faria AP, Barbaro NR, Gordo WM, Modolo RG, Pinho C et al. Deregulation of adipokines related to target organ damage on resistant hypertension. J Hum Hypertens 2014;28:388-92.
9. Scotece M, Conde J, Lopez V, Lago F, Pino J, Gomez-Reino JJ et al. Adiponectin and leptin: new targets in inflammation. Basic Clin Pharmacol Toxicol 2014;114:97-102.
10. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007;49:1455-61.
11. Ong KL, Li M, Tso AW, Xu A, Cherny SS, Sham PC et al. Association of genetic variants in the adiponectin gene with adiponectin level and hypertension in Hong Kong Chinese. Eur J Endocrinol 2010;163:251-7.
12. de Faria AP, Demacq C, Figueiredo VN, Moraes CH, Santos RC, Sabbatini AR et al. Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension. Hypertens Res 2013;36:1067-72.
13. Hivert MF, Manning AK, McAteer JB, Florez JC, Dupuis J, Fox CS et al. Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits: the Framingham Offspring Study. Diabetes 2008;57:3353-9.
14. Heid IM, Wagner SA, Gohlke H, Iglseder B, Mueller JC, Cip P et al. Genetic architecture of the APM1 gene and its influence on adiponectin plasma levels and parameters of the metabolic syndrome in 1, 727 healthy Caucasians. Diabetes 2006;55:375-84.
15. Leu HB, Chung CM, Lin SJ, Jong YS, Pan WH, Chen JW. Adiponectin gene polymorphism is selectively associated with the concomitant presence of metabolic syndrome and essential hypertension. PLoS ONE 2011;6:e19999.
16. Sun K, Li Y, Wei C, Tong Y, Zheng H, Guo Y. Recessive protective effect of ADIPOQ rs1501299 on cardiovascular diseases with type 2 diabetes: a meta-analysis. Mol Cell Endocrinol 2012;349:162-9.
17. Chiodini BD, Specchia C, Gori F, Barlera S, D'Orazio A, Pietri S et al. Adiponectin gene polymorphisms and their effect on the risk of myocardial infarction and type 2 diabetes: an association study in an Italian population. Ther Adv Cardiovasc Dis 2010;4:223-30.
18. de Souza WA, Sabha M, de Faveri Favero F, Bergsten-Mendes G, Yugar-Toledo JC, Moreno H. Intensive monitoring of adherence to treatment helps to identify "true" resistant hypertension. J Clin Hypertens (Greenwich) 2009;11:183-91.
19. Francischetti EA, Celoria BM, Duarte SF, da Silva EG, Santos IJ, Cabello PH et al. Hypoadiponectinemia is associated with blood pressure increase in obese insulin-resistant individuals. Metabolism 2007;56:1464-9.
20. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
21. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-605.
22. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
23. Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 2002;11:2607-14.
24. Zhang D, Ma J, Brismar K, Efendic S, Gu HF. A single nucleotide polymorphism alters the sequence of SP1 binding site in the adiponectin promoter region and is associated with diabetic nephropathy among type 1 diabetic patients in the Genetics of Kidneys in Diabetes Study. J Diabetes Complications 2009;23:265-72.
25. Laumen H, Saningong AD, Heid IM, Hess J, Herder C, Claussnitzer M et al. Functional characterization of promoter variants of the adiponectin gene complemented by epidemiological data. Diabetes 2009;58:984-91.
26. Yang Y, Zhang F, Ding R, Wang Y, Lei H, Hu D. Association of ADIPOQ gene polymorphisms and coronary artery disease risk: a meta-analysis based on 12 465 subjects. Thromb Res 2012;130:58-64.
27. Xi B, He D, Wang Q, Xue J, Liu M, Li J. Common polymorphisms (rs2241766 and rs1501299) in the ADIPOQ gene are not associated with hypertension susceptibility among the Chinese. Mol Biol Rep 2012;39:8771-5.
28. Zhao T, Zhao J. Genetic effects of adiponectin on blood lipids and blood pressure. Clin Endocrinol (Oxf) 2011;74:214-22.
29. Qiao L, Maclean PS, Schaack J, Orlicky DJ, Darimont C, Pagliassotti M et al. C/EBPalpha regulates human adiponectin gene transcription through an intronic enhancer. Diabetes 2005;54:1744-54.
30. Melistas L, Mantzoros CS, Kontogianni M, Antonopoulou S, Ordovas JM, Yiannakouris N. Association of the +45T>G and +276G>T polymorphisms in the adiponectin gene with insulin resistance in nondiabetic Greek women. Eur J Endocrinol 2009;161:845-52.
31. Yang WS, Tsou PL, Lee WJ, Tseng DL, Chen CL, Peng CC et al. Allele-specific differential expression of a common adiponectin gene polymorphism related to obesity. J Mol Med (Berl) 2003;81:428-34.
32. Quinaglia T, Martins LC, Figueiredo VN, Santos RC, Yugar-Toledo JC, Martin JF et al. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens 2011;25:656-64.
33. de Haro Moraes C, Figueiredo VN, de Faria AP, Barbaro NR, Sabbatini AR, Quinaglia T et al. High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension. J Hum Hypertens 2013;27:225-30.
34. Faria AP, Sabbatini AR, Coca A, Moreno H. Phenotypic characteristics of resistant hypertension in the Brazilian population. Arq Bras Cardiol 2013;100:579-82.
35. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008;168:1159-64.
36. da Silva AA, do Carmo J, Dubinion J, Hall JE. The role of the sympathetic nervous system in obesity-related hypertension. Curr Hypertens Rep 2009;11:206-11.
37. Fang C, Lei J, Zhou SX, Zhang YL, Yuan GY, Wang JF. Association of higher resistin levels with inflammatory activation and endothelial dysfunction in patients with essential hypertension. Chin Med J (Engl) 2013;126:646-9.
38. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008;117:2253-61.
39. Kunes J, Zicha J. The interaction of genetic and environmental factors in the etiology of hypertension. Physiol Res 2009;58(Suppl 2):S33-41.
40. Bader JS. The relative power of SNPs and haplotype as genetic markers for association tests. Pharmacogenomics 2001;2:11-24.
41. Pollin TI, Tanner K, O'Connell JR, Ott SH, Damcott CM, Shuldiner AR et al. Linkage of plasma adiponectin levels to 3q27 explained by association with variation in the APM1 gene. Diabetes 2005;54:268-74.
42. Fontana V, de Faria AP, Oliveira-Paula GH, Silva PS, Biagi C, Tanus-Santos JE et al. Effects of angiotensin-converting enzyme inhibition on leptin and adiponectin levels in essential hypertension. Basic Clin Pharmacol Toxicol 2014;114:472-5.
43. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76-81.